Lipoatrophy : The Lipo-Med Link - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
POZ Focus

Back to home » HIV 101 » POZ Focus » Lipoatrophy

Table of Contents

Saving Face—and Arms and Legs

The Latest on “Lipo”

Fat Facts

The Lipo-Med Link

Looking for Lipo

About Face

Willing to Experiment

Looking At Options

Click here to download
a copy of Lipoatrophy
(Nov. 07).

What You're Talking About
Losing Hope (blog) (22 comments)

Mad That Bill Maher Promoted a Quack AIDS Doc? Then Do This. (20 comments)

You Can't Hurry Love (14 comments)

I Watched Charlie Sheen on The Dr. Oz Show So You Don't Have To (blog) (14 comments)

Charlie Sheen S&%ts On 30 Years of AIDS Activism (blog) (14 comments)

Remember Their Names: World AIDS Day 2015 (blog) (13 comments)
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


The Lipo-Med Link

by David Evans

They’re all lifesaving, but some can be body changing. How fat-friendly is your drug regimen?

If you’re hoping to avoid lipoatrophy or possibly reverse it, a key issue to consider is your choice of drugs for your antiretroviral treatment regimen. Contrary to popular belief, protease inhibitors have not been shown to be a cause of lipoatrophy, although they have been linked to problems involving triglycerides and cholesterol. Research suggests that some nucleoside analogue reverse transcriptase inhibitors, or “nukes,” are likely the reason. But they may not be the only one—non-nucleoside reverse transcriptase inhibitors, or “non-nukes,” may also contribute.

When researchers first began looking for the causes of lipoatrophy, they suspected it might be due to damage some antiretroviral drugs can do to mitochondria, the power generators of human cells. If mitochondria are damaged, cells can’t repair themselves or multiply. In the case of lipoatrophy, scientists believed that damaged fat cells were being cleared from the body without any new ones being made to take their place. Some nukes, it turned out, ended up being the mitochondria-damaging offenders.

The nuke Zerit (stavudine) has been linked to lipoatrophy. To a lesser extent, zidovudine (AZT)—found in Retrovir, Combivir and Trizivir—has been implicated as well. In clinical trials, patients who started HIV treatment with stavudine or zidovudine were more likely to develop lipoatrophy than those taking the nukes abacavir (found in Ziagen, Epzicom and Trizivir) or tenofovir (found in Viread, Truvada and Atripla).          

To help lower the risk of lipoatrophy, many docs avoid—or at least delay—the use of suspect nukes. Eric Daar, MD, chief of HIV medicine at the Harbor-UCLA Medical Center, employs this strategy. He says, “We’re not using [stavudine]—and we’re also using less [zidovudine]. When we do use [zidovudine], we’re looking carefully for lipoatrophy, and if we notice it we talk about making an early switch.”

Is avoiding these nukes resulting in fewer people developing lipoatrophy? “I believe this is true,” says Dr. Daar.

Nuke avoidance, however, isn’t always possible. Ricky Hsu, MD, an HIV specialist in private practice in New York City, stresses that people starting HIV treatment for the first time can and should avoid these meds, but they may become necessary down the line if drug-resistant HIV becomes a problem. “I want to make sure if patients need to use them that they aren’t overly stressed about going on them,” he says. “There are new experimental treatments coming, and maybe one day soon we can stop using [these drugs] altogether, but for now they are what we have.”

While the nukes deserve their place at the top of the fat-loss list, other HIV drugs also deserve scrutiny. Early lipoatrophy research suggested that protease inhibitors might be to blame. While it’s possible that these drugs can affect how fat cells reproduce, there haven’t been any large studies indicting them as a cause.

A recent AIDS Clinical Trials Group study, ACTG 5142, unexpectedly found that the non-nuke Sustiva was associated with fat loss in the arms and legs. The trial compared three treatment regimens: Sustiva with two nukes, Kaletra with two nukes, and Kaletra with Sustiva and no nukes. Though the study found that Sustiva with two nukes controlled HIV slightly better than Kaletra and two nukes, it also showed that people on the Sustiva combo were more likely to have fat loss.

Dr. Hsu was surprised by the study results but points out that patients taking either stavudine or zidovudine were the most likely to develop lipoatrophy, compared with those using tenofovir. “Still,” he says, “the difference existed between Sustiva and Kaletra.”

Though Dr. Hsu hasn’t significantly changed the way he prescribes Sustiva, he says, “When I’m counseling patients, I can’t say to them that it definitively does not cause lipoatrophy.”

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[ Go to top ]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.